Caught between the rock and the hard place of most-favored nation (MFN) pricing and the threat of a hefty biopharma sector ...

The full rights to Taysha Gene Therapies Inc.’s lead gene therapy candidate are coming back to the company. In 2022, Astellas ...

There was a curate’s egg for Sanofi SA from this month’s meeting of the EMA’s Committee for Medicinal Products for Human Use, ...

Med-tech M&A activity totaled $4.84 billion in September, down slightly from $7.29 billion in July but stronger than August’s ...

Biopharma companies announced $73.38 billion in deals from 240 transactions during the third quarter (Q3) of 2025, bringing ...

Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic ...

Writing in the Journal of Medicinal Chemistry, researchers from Shenzhen University Medical School and collaborating ...

Xortx Therapeutics Inc. has entered into a binding term sheet to acquire a renal anti-fibrotic therapeutic program from ...

Merit Medical Systems Inc. looks to ingest Pentax Medical’s C2 cryoballoon through a $22 million asset purchase expected to ...

The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program ...

Aicuris Anti-Infective Cures AG is preparing to file for U.S. FDA approval after reporting positive phase III results for ...

Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...